199 related articles for article (PubMed ID: 19513632)
1. Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE.
Fontaine P; Gin H; Pinget M; Thivolet C; Hanaire H; Robert JJ; Marre M; Venkatanarasimhachar S
Adv Ther; 2009 May; 26(5):535-51. PubMed ID: 19513632
[TBL] [Abstract][Full Text] [Related]
2. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
3. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
4. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
Meneghini LF; Dornhorst A; Sreenan S;
Curr Med Res Opin; 2009 Apr; 25(4):1029-35. PubMed ID: 19281426
[TBL] [Abstract][Full Text] [Related]
5. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
Kurtoglu S; Atabek ME; Dizdarer C; Pirgon O; Isguven P; Emek S;
Pediatr Diabetes; 2009 Sep; 10(6):401-7. PubMed ID: 19220776
[TBL] [Abstract][Full Text] [Related]
6. Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes.
Chacra AR; Kipnes M; Ilag LL; Sarwat S; Giaconia J; Chan J;
Diabet Med; 2010 May; 27(5):563-9. PubMed ID: 20536953
[TBL] [Abstract][Full Text] [Related]
7. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
Meneghini LF; Rosenberg KH; Koenen C; Merilainen MJ; Lüddeke HJ
Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
[TBL] [Abstract][Full Text] [Related]
8. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
[TBL] [Abstract][Full Text] [Related]
9. An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update).
Philis-Tsimikas A
Expert Opin Pharmacother; 2008 Aug; 9(12):2181-95. PubMed ID: 18671472
[TBL] [Abstract][Full Text] [Related]
10. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study.
Sreenan S; Virkamäki A; Zhang K; Hansen JB;
Int J Clin Pract; 2008 Dec; 62(12):1971-80. PubMed ID: 19166444
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study.
Dornhorst A; Lüddeke HJ; Honka M; Ackermann RW; Meriläinen M; Gallwitz B; Sreenan S;
Curr Med Res Opin; 2008 Feb; 24(2):369-76. PubMed ID: 18096110
[TBL] [Abstract][Full Text] [Related]
12. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
Standl E; Lang H; Roberts A
Diabetes Technol Ther; 2004 Oct; 6(5):579-88. PubMed ID: 15628811
[TBL] [Abstract][Full Text] [Related]
13. [RESOLUTE Study in the Czech Republic: insulin glargine improves the compensation of type 2 diabetes in patients with unsatisfactory results of therapy with a combination of insulin detemir and oral antidiabetics. Results of the nonintervention RESOLUTE Project in the Czech Republic].
Kvapil M
Vnitr Lek; 2013 Sep; 59(9):800-6. PubMed ID: 24073952
[TBL] [Abstract][Full Text] [Related]
14. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes.
Marre M; Pinget M; Gin H; Thivolet C; Hanaire H; Robert JJ; Fontaine P
Diabetes Metab; 2009 Dec; 35(6):469-75. PubMed ID: 19914118
[TBL] [Abstract][Full Text] [Related]
15. [Once daily insulin detemir in patients with type 2 diabetes: results of German centers in a 6-month international observational study (SOLVE)].
Liebl A; Wilhelm B; Kaiser M
MMW Fortschr Med; 2012 Dec; 154 Suppl 4():102-9. PubMed ID: 23326928
[TBL] [Abstract][Full Text] [Related]
16. Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial.
Selam JL; Meneghini LF
Adv Ther; 2009 Feb; 26(2):194-207. PubMed ID: 19259629
[TBL] [Abstract][Full Text] [Related]
17. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
Vague P; Selam JL; Skeie S; De Leeuw I; Elte JW; Haahr H; Kristensen A; Draeger E
Diabetes Care; 2003 Mar; 26(3):590-6. PubMed ID: 12610006
[TBL] [Abstract][Full Text] [Related]
18. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.
Liebl A; Prager R; Binz K; Kaiser M; Bergenstal R; Gallwitz B;
Diabetes Obes Metab; 2009 Jan; 11(1):45-52. PubMed ID: 18643839
[TBL] [Abstract][Full Text] [Related]
19. PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort.
Lüddeke HJ; Sreenan S; Aczel S; Maxeiner S; Yenigun M; Kozlovski P; Gydesen H; Dornhorst A;
Diabetes Obes Metab; 2007 May; 9(3):428-34. PubMed ID: 17391171
[TBL] [Abstract][Full Text] [Related]
20. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
Raslova K
Vasc Health Risk Manag; 2010 Jun; 6():399-410. PubMed ID: 20539842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
